Quotient Limited (QTNT)
Stock Price:
$6.63 USD
-0.12 (-1.78%)
Updated Aug 12, 2020 2:24 PM EDT - Market open
Key Info
| Market Cap |
534.66M |
| Revenue (ttm) |
33.41M |
| Net Income (ttm) |
-104.63M |
| Shares Out |
80.64M |
| EPS (ttm) |
-1.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$6.63 |
| Previous Close |
$6.75 |
| Change ($) |
-0.12 |
| Change (%) |
-1.78% |
| Day's Open |
6.82 |
| Day's Range |
6.60 - 6.99 |
| Day's Volume |
247,402 |
| 52-Week Range |
2.40 - 11.10 |
More Stats
| Market Cap |
534.66M |
| Enterprise Value |
610.59M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
80.64M |
| Float |
46.87M |
| EPS (basic) |
-1.4 |
| EPS (diluted) |
-1.39 |
| FCF / Share |
-1.05 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.45M |
| Short Ratio |
9.20 |
| Short % of Float |
8.72% |
| Beta |
2.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
16.00 |
| PB Ratio |
31.00 |
| Revenue |
33.41M |
| Operating Income |
-81.99M |
| Net Income |
-104.63M |
| Free Cash Flow |
-84.69M |
| Net Cash |
-75.93M |
| Net Cash / Share |
-0.94 |
| Gross Margin |
44.46% |
| Operating Margin |
-245.40% |
| Profit Margin |
-313.20% |
| FCF Margin |
-253.48% |
| ROA |
-25.36% |
| ROE |
-489.97% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.50*
(103.62% upside)
Low
13.0
Current: $6.63
High
14.0
Target: 13.50
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 32.66 | 29.13 | 24.73 | 22.23 | 18.52 | 18.41 | 19.76 | 14.37 | 12.22 | 10.03 |
| Revenue Growth | 12.09% | 17.8% | 11.27% | 20% | 0.62% | -6.82% | 37.46% | 17.61% | 21.78% | - |
| Gross Profit | 14.86 | 11.90 | 14.26 | 11.38 | 8.86 | 8.65 | 11.35 | 7.20 | 5.47 | 4.41 |
| Operating Income | -80.69 | -78.96 | -69.99 | -74.06 | -49.09 | -29.71 | -8.89 | -4.49 | -3.96 | -4.10 |
| Net Income | -103 | -105 | -82.34 | -85.07 | -33.88 | -59.06 | -10.17 | -4.71 | -4.47 | -4.62 |
| Shares Outstanding | 71.61 | 54.87 | 40.84 | 28.15 | 19.56 | 14.77 | 0.19 | 0.07 | 0.06 | 0.06 |
| Earnings Per Share | -1.44 | -1.92 | -2.02 | -3.02 | -1.73 | -4.00 | -54.41 | -62.97 | -78.04 | -81.16 |
| Operating Cash Flow | -80.65 | -75.66 | -68.42 | -56.20 | -46.97 | -26.59 | -4.38 | -3.62 | -3.07 | -3.56 |
| Capital Expenditures | -4.60 | -4.79 | -1.86 | -20.16 | -28.91 | -23.85 | -7.23 | -0.89 | -0.35 | -0.09 |
| Free Cash Flow | -85.24 | -80.45 | -70.28 | -76.36 | -75.88 | -50.45 | -11.61 | -4.51 | -3.42 | -3.65 |
| Cash & Equivalents | 130 | 102 | 30.87 | 25.85 | 44.10 | 37.53 | 7.19 | 4.22 | 4.35 | 0.00 |
| Total Debt | 178 | 123 | 87.00 | 82.25 | 30.79 | 14.87 | 15.44 | 3.51 | 3.10 | - |
| Net Cash / Debt | -47.88 | -20.86 | -56.13 | -56.40 | 13.32 | 22.66 | -8.25 | 0.71 | 1.26 | 0.00 |
| Assets | 226 | 178 | 124 | 110 | 120 | 80.20 | 29.81 | 12.89 | 12.36 | - |
| Liabilities | 232 | 176 | 138 | 134 | 73.03 | 81.82 | 30.58 | 7.93 | 7.29 | - |
| Book Value | -5.53 | 1.71 | -14.63 | -24.09 | 46.72 | -1.62 | -31.54 | -23.06 | -18.69 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Quotient Limited |
| Country |
Switzerland |
| Employees |
420 |
| CEO |
Franz Walt |
Stock Information
| Ticker Symbol |
QTNT |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: QTNT |
| IPO Date |
April 25, 2014 |
Description
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.